Thompson SW and Tonge D |
Bone cancer gain without the pain. |
2000 |
Nat. Med. |
pmid:10802700
|
Honore P et al. |
Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. |
2000 |
Nat. Med. |
pmid:10802707
|
Onyia JE et al. |
In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. |
2000 |
J. Bone Miner. Res. |
pmid:10804015
|
Malyankar UM et al. |
Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. |
2000 |
J. Biol. Chem. |
pmid:10811631
|
Kanzawa M et al. |
Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. |
2000 |
Eur. J. Endocrinol. |
pmid:10822231
|
Thirunavukkarasu K et al. |
The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. |
2000 |
J. Biol. Chem. |
pmid:10833509
|
Günther T and Schinke T |
Mouse genetics have uncovered new paradigms in bone biology. |
2000 |
Trends Endocrinol. Metab. |
pmid:10856921
|
Rani CS and MacDougall M |
Dental cells express factors that regulate bone resorption. |
2000 |
Mol. Cell Biol. Res. Commun. |
pmid:10860862
|
Tsurukai T et al. |
Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis. |
2000 |
J. Bone Miner. Metab. |
pmid:10874596
|
Hofbauer LC and Heufelder AE |
Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. |
2000 |
J. Clin. Endocrinol. Metab. |
pmid:10902778
|
Lacey DL et al. |
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. |
2000 |
Am. J. Pathol. |
pmid:10934148
|
Quinn JM et al. |
Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. |
2000 |
J. Bone Miner. Res. |
pmid:10934644
|
Min H et al. |
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. |
2000 |
J. Exp. Med. |
pmid:10952716
|
Shiba H et al. |
Effects of ageing on proliferative ability, and the expressions of secreted protein, acidic and rich in cysteine (SPARC) and osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human periodontal ligament cells. |
2000 |
Mech. Ageing Dev. |
pmid:10958924
|
López FJ |
New approaches to the treatment of osteoporosis. |
2000 |
Curr Opin Chem Biol |
pmid:10959765
|
Udagawa N et al. |
Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. |
2000 |
Endocrinology |
pmid:10965921
|
Yasuda H |
[A new paradigm of osteoclast biology: discovery of OCIF and ODF]. |
2000 |
Seikagaku |
pmid:10967683
|
Teitelbaum SL |
Bone resorption by osteoclasts. |
2000 |
Science |
pmid:10968780
|
Nakashima T et al. |
Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. |
2000 |
Biochem. Biophys. Res. Commun. |
pmid:10973797
|
Itoh K et al. |
Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. |
2000 |
J. Bone Miner. Res. |
pmid:10976996
|